In conclusion, the current study demonstrated that anti-BCMA CAR-modified Vγ9Vδ2 T cells are myeloma-reactive in vitro and in vivo, suggesting them as a potential candidate for tumor immunotherapy against MM. The gene discussed is TNFRSF17; the disease is neoplasm.